Diabetic Kidney Disease
Conditions
Interventions
Experimental group:Based on the maximum tolerated ACEI or ARB treatment, the initial dose of finerenone tablets was 10mg once daily. After 1 month, the dose was increased from 10 to 20mg if the serum
control group:Based on the maximum tolerable dose of ACEI or ARB treatment, the initial dose of Dapagliflozin tablets is 5 mg/day, which can be increased to 10 mg/day according to the blood glucose co
Sponsors
The First Affiliated Hospital of Shihezi University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old and diagnosed with type 2 diabetes; 2. Diagnosis of DKD according to the Guidelines for the Prevention and Treatment of Diabetic Nephropathy in China (2021 Edition); 3. Glomerular filtration rate (eGFR) >=30mL/(min·1.73 m^2) 4.UACR >= 30mg/g; 5. Treatment with ACEi or ARB at the maximum tolerated dose for = four weeks 6. No use of SGLT2 inhibitors and MRA in the past 3 months 7. Those who are aware of this study, express their willingness to participate in this study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Non-diabetic kidney disease; 2. EF value=160/100mmHg; 4. Glycosylated hemoglobin > = 10% 5. Kidney atrophy 6. Patients with recent acute and chronic infection, gastrointestinal bleeding, malignant tumors and abnormal liver function 7. Adrenal insufficiency 8. Hyperkalemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary protein excretion rate;Rate of decline in glomerular filtration rate;UACR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum interleukin-6;monocyte chemotactic protein-1(MCP-1);TNF-a;EF%; | — |
Countries
China
Contacts
Public ContactGuorui Zhang
The First Affiliated Hospital of Shihezi University
Outcome results
None listed